We have an exciting lineup of speakers for this year's 4th Annual Conference on Precision Psychiatry!

Students, fellows, interns, and trainees can register for free!

Register today at mghcme.org/precision2024

Questions can be directed to [email protected]

Dr. James McKowen MGH Psychiatry:
Climate anxiety is a real thing -
“Young people are bringing this to our clinical space, sharing their anxieties, sharing their worries about the future and it’s getting in their way.'

When a patient does not respond to 2 or more antidepressant trials, what's next? Switch? Add an atypical? TMS?

The ASCERTAIN-TRD study has some answers:
mghpsychnews.org/for-treatment-…

Our interest in psychedelics for the treatment of psychiatric illness is barreling ahead. But have we thought enough about informed consent?
Commentary from Rebecca Brendel MD, JD via JAMA Network Open
bityl.co/PIfk

Improving health among SGM people requires a foundation of equity and inclusion within a payer’s own organization. New research from Alex Keuroghlian, MD in JAMA Health Forum

Honored to be chosen as the #JerilynRoss lecturer at the #ADAA2024 . She was such a trailblazer in creating awareness about the need for treatment for #anxiety disorders, particularly in #women & providing a treatment center to target these. A wonderful fit with ICON-✘'s mission

When a patient does not respond to 2 or more antidepressant trials, what's next? Switch? Add an atypical? TMS?

The ASCERTAIN-TRD study has some answers:
mghpsychnews.org/for-treatment-…

3 luminaries in the field of neurology celebrating the Potemkin prize awarded to Dr. Francisco Lopera at the American Academy of Neurology. ⁦Yakeel T. Quiroz, PhD (she/her)⁩ ⁦MGH Multicultural Alz Prev Prog⁩ ⁦MGH Psychiatry⁩ ⁦Liliana Ramirez Gomez, M.D.⁩ ⁦Universidad de Antioquia⁩

Daphne Holt, MD PhD and her team use neuroimaging to study #loneliness and social isolation.

Research from Tim Wilens, MD et al:
Later initiation of stimulant therapy for #ADHD in kids associated with subsequent increase in risk of stimulant misuse.

bityl.co/PAh6+

📢Drs Jill M. Goldstein, Ph.D will be speaking at #ADAA2024 tomorrow in Boston! Attend her talk at 1pm for insights on ' #Depression and #Comorbidity with General Medicine: Discoveries & Treatment Viewed through a #SexDifferences Lens' Don't miss out !

From Mason Marks, MD, JD, Rebecca Brendel MD, JD et al:

“Psychedelics have unique properties that complicate the informed consent process. They often produce intense subjective experiences that are difficult to explain, predict, or comprehend, especially for #psychedelic -naive individuals”

Addressing misinformation regarding psychiatric illness and the use of antidepressants:

Midlife mortality from deaths of despair (suicide, drug overdose, alcoholic liver disease) has risen sharply since the concept was defined, with particularly large increases for American Indian or Alaska Native and Black individuals from 1999 to 2022. ja.ma/3PVrXsF

Discrimination leads to higher risk of #HIV in #transgender women. Alex Keuroghlian, MD from MGH Psychiatry Fenway Health: Clinicians can provide critical support through culturally responsive care, considering all aspects of a patient’s experiences

statnews.com/2024/01/25/tra…

DEI initiatives are at risk. How will this affect healthcare?
Read this commentary from Aderonke Pederson, MD (Ronke) via MedPage Today

mghpsychnews.org/aderonke-peder…

When using lamotrigine, we always discuss risk of Stevens Johnsons syndrome. But what about cardia side effects?

This clear and concise video from Scott Beach, MD covers cardiac conduction risks and guidelines re: use of lamotrigine.

4 antipsychotics stand out for combined dopamine-serotonin effects:
Aripiprazole, cariprazine, brexpiprazole, lumateperone

Of these, the first 3 improved negative symptoms of #schizophrenia in new analysis of 20 trials:
pubmed.ncbi.nlm.nih.gov/36979900

I'd add clozapine to list

Exciting research from Sabine Wilhelm, PhD and colleagues Center for OCD and Related Disorders (CORD) Center for Digital Mental Health explores app delivering CBT for #depression .

mental.jmir.org/2024/1/e53998

When a patient does not respond to 2 or more antidepressant trials, what's next? Switch? Add an atypical? TMS?

The ASCERTAIN-TRD study has some answers:
mghpsychnews.org/for-treatment-…